[Skip to Content]
[Skip to Content Landing]
August 1966

Controlled Sequential Trials of Carbamazepine in Trigeminal Neuralgia

Author Affiliations

From the Medical Department, Western Section, Geigy Pharmaceuticals (Dr. Rockliff), and the Division of Medicine (Neurology), Cedars-Sinai Medical Center, and the Department of Neurology, University of Southern California School of Medicine (Dr. Davis), Los Angeles.

Arch Neurol. 1966;15(2):129-136. doi:10.1001/archneur.1966.00470140019003

TIC DOULOUREUX is an often incapacitating affliction for which no completely satisfactory medical treatment has been available. While early observations that diphenylhydantoin has beneficial effects have been generally confirmed,1-4 results with this drug are variable. Low doses are often ineffective, while the high dosages sometimes required for symptom control are poorly tolerated.

Recently, Blom5,6 and others7-13 have reported that the paroxysmal pain of trigeminal neuralgia is promptly and consistently suppressed by the administration of carbamazepine (Tegretol), an iminostilbene derivative with anticonvulsant activity. Chemically, the compound is 5 carbamyl-5H-dibenz (b,f )-azepine, and, as indicated by the structural formula (Fig 1), it is related to the antidepressant imipramine, but not to the hydantoins. While results with carbamazepine in typical tic douloureux are reported to be highly promising, the benefits observed in postherpetic and atypical facial neuralgias have been minimal. No controlled clinical trials with carbamazepine have been reported.